CA2229590C - Pharmaceutical composition containing inhibitors of interferon- gamma - Google Patents

Pharmaceutical composition containing inhibitors of interferon- gamma Download PDF

Info

Publication number
CA2229590C
CA2229590C CA2229590A CA2229590A CA2229590C CA 2229590 C CA2229590 C CA 2229590C CA 2229590 A CA2229590 A CA 2229590A CA 2229590 A CA2229590 A CA 2229590A CA 2229590 C CA2229590 C CA 2229590C
Authority
CA
Canada
Prior art keywords
ifn
gamma
inhibitor
pharmaceutical composition
healing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2229590A
Other languages
English (en)
French (fr)
Other versions
CA2229590A1 (en
Inventor
Mark William James Ferguson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renovo Ltd
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Priority to CA002614655A priority Critical patent/CA2614655A1/en
Publication of CA2229590A1 publication Critical patent/CA2229590A1/en
Application granted granted Critical
Publication of CA2229590C publication Critical patent/CA2229590C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
CA2229590A 1995-08-18 1996-08-09 Pharmaceutical composition containing inhibitors of interferon- gamma Expired - Fee Related CA2229590C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002614655A CA2614655A1 (en) 1995-08-18 1996-08-09 Pharmaceutical composition containing inhibitors of interferon-gamma

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9516967A GB2304342A (en) 1995-08-18 1995-08-18 Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
GB9516967.8 1995-08-18
PCT/GB1996/001949 WO1997007136A2 (en) 1995-08-18 1996-08-09 Pharmaceutical composition containing inhibitors of interferon-gamma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002614655A Division CA2614655A1 (en) 1995-08-18 1996-08-09 Pharmaceutical composition containing inhibitors of interferon-gamma

Publications (2)

Publication Number Publication Date
CA2229590A1 CA2229590A1 (en) 1997-02-27
CA2229590C true CA2229590C (en) 2010-10-12

Family

ID=10779448

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2229590A Expired - Fee Related CA2229590C (en) 1995-08-18 1996-08-09 Pharmaceutical composition containing inhibitors of interferon- gamma

Country Status (12)

Country Link
EP (2) EP0845007B1 (enExample)
JP (2) JP4070809B2 (enExample)
AT (2) ATE208402T1 (enExample)
AU (1) AU713809B2 (enExample)
CA (1) CA2229590C (enExample)
DE (2) DE69626050T2 (enExample)
DK (2) DK0845007T3 (enExample)
ES (2) ES2192018T3 (enExample)
GB (1) GB2304342A (enExample)
PT (2) PT845007E (enExample)
WO (1) WO1997007136A2 (enExample)
ZA (1) ZA966953B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1336654A1 (en) 1998-12-09 2003-08-20 Protein Design Labs, Inc. Method of treating psoriasis using anti-gamma interferon antibody
EP1180037A2 (en) * 1999-05-26 2002-02-20 The Brigham and Women's Hospital Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin
US6710025B1 (en) 1999-05-26 2004-03-23 The Brigham And Women's Hospital, Inc. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
WO2008099829A1 (ja) * 2007-02-14 2008-08-21 Japan Science And Technology Agency 実験動物の腸管癒着を形成する方法、腸管癒着実験動物の製造方法、腸管癒着抑制剤のスクリーニング方法及び腸管癒着抑制剤
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
RU2539383C1 (ru) * 2013-11-29 2015-01-20 Закрытое акционерное общество "ФИРН М" (ЗАО "ФИРН М") Фармацевтическая композиция для лечения трофических язв и длительно незаживающих ран различной этиологии в виде мази

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
DE3773387D1 (de) * 1986-06-17 1991-10-31 Biogen Inc Kombination von gammainterferonen und antientzuendungsmitteln oder antipyretischen mitteln zur behandlung von krankheiten.
NL8700927A (nl) * 1987-04-16 1988-11-16 Stichting Rega V Z W Anti-interferon-gamma-antilichamen; en hun therapeutische toepassing.
CA1335792C (en) * 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
IL88378A (en) * 1988-11-14 2000-11-21 Yeda Res & Dev Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
SG43205A1 (en) * 1988-12-19 1997-10-17 American Cyanamid Co A method for the treatment of endotoxic shock in a mammal
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
DE69024398T2 (de) * 1989-04-19 1996-06-13 Hoffmann La Roche Auflösbare Interferon-gamma-Rezeptoren sowie Verfahren zu deren Herstellung
IT1231727B (it) * 1989-08-11 1991-12-21 Enrico Savoldi Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone.
IL91562A0 (en) * 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
ZA917669B (en) * 1990-09-27 1992-08-26 Schering Corp Antagonists of human gamma interferon
EP0526630A4 (en) * 1991-02-22 1993-08-11 Amgen Inc. Use of gm-csf and g-csf to promote accelerated wound healing
NL9101290A (nl) * 1991-07-23 1993-02-16 Stichting Rega V Z W Recombinant dna-molecuul voor de expressie van een fv-fragment van een antilichaam.
DE4234380A1 (de) * 1992-10-06 1994-04-07 Schering Ag Verwendung von Dopaminagonisten zur Aktivierung des gamma-Interferon-Produktion
CA2149785A1 (en) * 1992-11-20 1994-06-09 Gail F. Seelig Antagonists of human gamma interferon
DE69322289T2 (de) * 1992-12-29 1999-05-20 Genentech, Inc., South San Francisco, Calif. Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
JPH09506263A (ja) * 1993-12-09 1997-06-24 アゲット，ミヒェル ＩＦＮ−γレセプターβ−鎖およびその誘導体

Also Published As

Publication number Publication date
EP0845007A2 (en) 1998-06-03
DK0845007T3 (da) 2001-12-17
ATE231728T1 (de) 2003-02-15
ZA966953B (en) 1998-02-16
EP0845007B1 (en) 2001-11-07
ATE208402T1 (de) 2001-11-15
PT845007E (pt) 2002-03-28
JP4070809B2 (ja) 2008-04-02
JPH11511160A (ja) 1999-09-28
WO1997007136A3 (en) 1997-08-21
DK0972521T3 (da) 2003-05-05
JP4616291B2 (ja) 2011-01-19
JP2007119497A (ja) 2007-05-17
ES2192018T3 (es) 2003-09-16
DE69616803D1 (de) 2001-12-13
DE69616803T2 (de) 2002-06-20
GB9516967D0 (en) 1995-10-18
WO1997007136A2 (en) 1997-02-27
AU6707196A (en) 1997-03-12
ES2164911T3 (es) 2002-03-01
HK1023516A1 (en) 2000-09-15
PT972521E (pt) 2003-06-30
CA2229590A1 (en) 1997-02-27
DE69626050T2 (de) 2004-01-22
AU713809B2 (en) 1999-12-09
DE69626050D1 (de) 2003-03-06
EP0972521A1 (en) 2000-01-19
EP0972521B1 (en) 2003-01-29
GB2304342A (en) 1997-03-19

Similar Documents

Publication Publication Date Title
EP0783893B1 (en) Inhibition of abnormal growth of synovial cells using il-6 antagonist as active ingredient
CA2185565C (en) Use of il-12 and il-12 antagonists in the treatment of autoimmune diseases
US8017121B2 (en) Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US5888510A (en) Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
JP3333507B2 (ja) 創傷治療
US7220413B2 (en) Pharmaceutical composition containing inhibitors of interferon-γ
Nicoletti et al. The effects of a nonimmunogenic form of murine soluble interferon-gamma receptor on the development of autoimmune diabetes in the NOD mouse
Hiltz et al. α-MSH peptides inhibit acute inflammation induced in mice by rIL-1β, rIL-6, rTNF-α and endogenous pyrogen but not that caused by LTB4, PAF and rIL-8
EP0968723B1 (en) Healing of wounds or fibrotic disorders using at least one agent against a growth factor
EP1651266B1 (en) Administration of anti-tnf-alpha f(ab')2 antibody fragments
JP4616291B2 (ja) インターフェロン−ガンマスティミュレーター含有医薬組成物
US7727520B2 (en) Method of promoting the healing of a chronic wound
US20070020233A1 (en) Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
EP1719522B1 (en) Medicinal composition comprising TCF-II
AU747598B2 (en) Pharmaceutical composition containing stimulators of interferon-gamma
STEVENS et al. Synergistic immunosuppressive effects of monoclonal antibodies specific for interferon-gamma and tumor necrosis factor alpha: a skin transplantation study in the rhesus monkey
CA2614655A1 (en) Pharmaceutical composition containing inhibitors of interferon-gamma
HK1023516B (en) Pharmaceutical composition containing stimulators of interferon-gamma
DE69102265T2 (de) Immunkomplexe.
JPS62252729A (ja) 造血機能回復促進剤
Oncostatin Regulation of Inflammatory Responses by
HK1024419A (en) Healing of wounds or fibrotic disorders using at least one agent against a growth factor

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed